Precision oncology,
made smart.
ONCO X — the Molecular Diagnostics vertical of Biosite Research — is bringing fast, ultra-sensitive genomic tests to the Indian labs and oncologists that already serve most of the country's cancer patients.
Built for the cancers Indian oncologists see every week.
Four indications — one platform of fast, ultra-sensitive molecular tests. Click any card to explore the science, the workflow, and how to order.
Lung Cancer
NSCLC — 3 technologies covering tissue and liquid biopsy, plus a first-line cancer resistance test.
Colorectal Cancer
Actionable biomarker panel for metastatic CRC — RAS, BRAF, MSI and beyond.
Bladder Cancer
Molecular diagnostics for MIBC and NMIBC — early detection & stratification.
Measurable Residual Disease
Ultra-sensitive MRD monitoring — detect recurrence months before imaging.
The numbers that change how oncologists treat.
vs ~25% NGS norm
Leading with passion
and purpose.
Dr Aditi Datta, our founder and CEO, is building ONCO X on a single conviction: no advanced-cancer patient in India should start therapy without the molecular test that decides which therapy is right for them.
See the full teamWhen the biopsy was quantity not sufficient, the result still had to count.
L.G., 71, presented with a large pleural effusion. His pleural biopsy confirmed NSCLC — but at 10–15% tumour content it was deemed insufficient for NGS or sequential PCR. With no molecular result, he was started on chemotherapy, which he did not tolerate well.
LiquiSmart returned an actionable EGFR L858R mutation from the same low-content sample — and targeted therapy could begin within 34 hours.
Read the full case →One workflow change, a very different treatment timeline.
Across Indian oncology practice, the same shift is playing out: PulmoSmart and LiquiSmart replace a three-week reference-lab loop with a next-day answer, on standard PCR hardware the lab already runs. Chemotherapy is no longer the default first line just because the molecular result never made it back in time.
How we're closing the India testing gap →
Bring molecular precision to your patients.
Let's talk.
For clinicians, laboratory partners, investors, press — or anyone who wants to change how precision oncology reaches Indian patients.
connect@oncox.in